4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Insmed Incorporated (INSM) operates in the Biotechnology industry and is headquartered in Bridgewater, United States with about 1,664 employees. Its market capitalization is roughly $26 billion. In the fiscal year ended 2025-12-31, INSM reported $606M in revenue and ($1.3B) in net income.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Interactive charts & full statements → Open the INSM valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $606M | $364M | $305M | $245M | — |
| Gross Profit | $484M | $278M | $240M | $190M | — |
| Operating Income (EBIT) | ($995M) | ($787M) | ($681M) | ($478M) | — |
| Net Income | ($1.3B) | ($914M) | ($750M) | ($482M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $306M | $264M | $142M | $107M | $93M | — |
| Gross Profit | $258M | $220M | $113M | $79M | $72M | — |
| Operating Income (EBIT) | ($200M) | ($250M) | ($261M) | ($254M) | ($230M) | — |
| Net Income | ($164M) | ($328M) | ($370M) | ($322M) | ($257M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $2.3B | $2.0B | $1.3B | $1.7B | — |
| Total Liabilities | $1.5B | $1.7B | $1.7B | $1.6B | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INSM viewer.
About TickerBase · Data methodology & sources